Phase I study of regorafenib and sildenafil in advanced solid tumors.

被引：0
|
作者：
Poklepovic, Andrew Stewart [1 ]
Gordon, Sarah W. [1 ]
McGuire, William P. [1 ]
Thacker, Leroy R. [1 ]
Deng, Xiaoyan [1 ]
Tombes, Mary Beth [1 ]
Shrader, Ellen [1 ]
Ryan, Alison A. [1 ]
Kmieciak, Maciej [1 ]
Dent, Paul [1 ]
机构：
[1] VCU Massey Canc Ctr, Richmond, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3593
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Gemcitabine and Docetaxel in patients with advanced solid tumors. A GETICS phase I trial
    Jaremtchuk, AV
    Zabra, JJ
    Ferro, A
    Aman, EF
    Alvarez, R
    Arroyo, G
    Marmissolle, F
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S290 - S290
  • [42] A phase 1 study of oral navelbine in patients with advanced solid tumors.
    Rajdev, L
    Dai, Q
    Mani, S
    Goldberg, G
    Baker, C
    Hoschander, S
    Sparano, J
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6137S - 6137S
  • [43] A phase I dose escalation and pharmacodynamic study of weekly administered AlbuleukinTM in patients with advanced solid tumors.
    Agarwala, SS
    Bukowski, RM
    Kirkwood, J
    Weiss, P
    Olencki, T
    Grzegorewski, KJ
    Melder, R
    Fox, RA
    Herpst, JM
    Gallant, G
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6230S - 6231S
  • [44] Phase I pharmacokinetic (PK) study of daily imatinib in combination with docetaxel for patients with advanced solid tumors.
    Chatta, GS
    Fakih, M
    Ramalingam, S
    Belani, CP
    Ramanathan, RK
    Zamboni, N
    Friedland, D
    Lis, D
    Tutchko, S
    Egorin, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 138S - 138S
  • [45] Phase I study of ABT-888 in combination with carboplatin and gemcitabine in subjects with advanced solid tumors.
    Bell-McGuinn, Katherine M.
    Gray, Heidi J.
    Fleming, Gini F.
    Cristea, Mihaela C.
    Medina, Diane M.
    Xiong, Hao
    Dudley, Matthew W.
    Dunbar, Martin
    Giranda, Vincent L.
    Luo, Yan
    McKee, Mark D.
    Martin, Lainie P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors.
    Wisinski, Kari Braun
    Tevaarwerk, Amye
    Bell, Maria
    Burkard, Mark E.
    Eickhoff, Jens C.
    Wilding, George
    LoConte, Noelle K.
    Traynor, Anne M.
    Hoang, Tien
    Heideman, Jennifer
    Kolesar, Jill
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.
    Xu, Ruihua
    Li, Yuhong
    Ji, Jiao
    Qiu, Miaozhen
    Zhang, Yang
    Liu, Wenqin
    Tian, Xiaohong
    Li, Su
    Wang, Hengbang
    Wang, Fenghua
    Zhang, Dongsheng
    Wang, Feng
    Wang, Zhiqiang
    Luo, Huiyan
    Zou, Benyan
    Wang, De shen
    Ren, Chao
    Jin, Ying
    Zhai, Yifan
    Yang, Dajun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] A phase I open label study evaluating VT1021 in patients with advanced solid tumors.
    Cieslewicz, Michael
    Mahalingam, Devalingam
    Harb, Wael A.
    Patnaik, Amita
    Liu, Joyce F.
    Juric, Dejan
    Bullock, Andrea J.
    Zheng, Lei
    Moore, Kathleen N.
    Patel, Manish R.
    Guttendorf, Robert
    Wang, Suming
    Kerstein, Kathy
    Berk, Gregory Ivan
    Watnick, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] A phase I study of safety and pharmacokinetics of NanoBB-1-Dox in patients with advanced solid tumors.
    Filon, Olga
    Krivorotko, Petr
    Kobyakov, Grigory
    Razjivina, Viktoria
    Maximenko, Olga
    Gelperina, Svetlana
    Kreuter, Joerg
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] A phase I study of veliparib (Vel) in combination with oxaliplatin (Ox) and capecitabine (Cap) in advanced solid tumors.
    Turk, Anita Ahmed
    Deming, Dustin A.
    Lubner, Sam Joseph
    Mulkerin, Daniel
    LoConte, Noelle K.
    Tevaarwerk, Amye
    Wisinski, Kari Braun
    Eickhoff, Jens C.
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345